Micro Therapeutics Ready to Market EMBOLYX for Peripheral Vascular Applications and Balloon Catheter in Europe; Company Granted CE Mark Clearance.IRVINE, Calif.--(BUSINESS WIRE)--May 12, 1999-- Marking the company's first commercial application of its EMBOLYX(TM) Liquid Embolic System Liquid Embolic System Therapeutics A fluid used for therapeutic embolization, administered via a pre-positioned microcatheter under continuous fluoroscopic monitoring , Micro Therapeutics Inc. (MTI MTI Ministry of Trade and Industry (Singapore) MTI Metal Treating Institute MTI Moving Target Indicator (radar) MTI Magyar Távirati Iroda (news agency in Budapest, Hungary) ) (Nasdaq:MTIX MTIX Moving Target Information Exploitation MTIX Moving Target Indicator Exploitation MTIX MetroTix, Inc. (Saint Louis, MO, USA) ) Wednesday announced it has received clearance to apply the CE Mark to its EMBOLYX system for peripheral vascular applications and Equinox equinox (ē`kwĭnŏks), either of two points on the celestial sphere where the ecliptic and the celestial equator intersect. The vernal equinox, also known as "the first point of Aries," is the point at which the sun appears to cross the (TM) Occlusion Balloon System in Europe. "We are ecstatic about the opportunity to begin selling this first application of our EMBOLYX technology, complemented by our Equinox Balloon System for neuro vascular applications, in Europe," said George Wallace, president and chief executive officer. "Broadening the applications for the EMBOLYX system beyond neuro vascular disorders currently under study, the European clearance allows for EMBOLYX to be marketed for such applications as the embolization embolization /em·bo·li·za·tion/ (em?bo-li-za´shun) 1. the process or condition of becoming an embolus. 2. therapeutic introduction of a substance into a vessel in order to occlude it. of arteriovenous malformations Arteriovenous Malformations Definition Arteriovenous malformations are blood vessel defects that occur before birth when the fetus is growing in the uterus (prenatal development). The blood vessels appear as a tangled mass of arteries and veins. (AVMs) and of certain hypervascular tumors located in the peripheral vascular system. Additionally, this clearance is the first in a series of applications for EMBOLYX that we intend to file in Europe, and we believe it is testament to our unique and highly competitive technology." Wallace also said the recent approval increases the total product lines approved for distribution in Europe to five lines which already includes the EASY RIDER(TM) Micro Catheter, FLOW RIDER(TM) Flow Directed Catheter and SilverSpeed(TM) Hydrophilic hydrophilic /hy·dro·phil·ic/ (-fil´ik) readily absorbing moisture; hygroscopic; having strongly polar groups that readily interact with water. hy·dro·phil·ic adj. Guidewire, MTI's neuro vascular access vascular access Clinical medicine The ability to enter the vascular system; the ease with which the vascular system can be entered for administering therapy or obtaining blood for testing and delivery products currently being distributed. Guidant Corp., the company's exclusive European distribution partner for neuro vascular products and products related to peripheral vascular applications of EMBOLYX, along with independent distributors, will be responsible for orders of these products in Europe. EMBOLYX is a vascular "blocking agent blocking agent n. A drug that blocks transmission of nerve impulses at an autonomic receptor site, autonomic synapse, or neuromuscular junction. ," delivered via micro catheters and released as a liquid that quickly transforms into a solid polymer mass thereby permanently filling the intended vessel or vascular defect. MTI's Equinox Balloon System is designed for use in blood vessels where selectively stopping or controlling blood flow is desired and it is capable of accessing small diameter vessels and tortuous anatomy. Accordingly, it may be used to arrest blood flow to distal sites to allow for embolization treatment of vascular abnormalities such as aneurysms. Micro Therapeutics, founded in 1993 and based in Irvine, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of vascular disease. Certain statements in this release are forward-looking and may involve risk and uncertainties, including, but not limited to, product development, demand and market acceptance risks, the impact of competitive products and pricing, regulatory approval and future product development. More information on factors which could affect Micro Therapeutic Inc.'s financial results is included in the company's prospectus dated Feb. 18, 1997, as well as in its Forms 10-QSB and 10-KSB, filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion